로딩 중…
지수 로딩 중…
SCM Lifescience Co., Ltd.
298060· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,375+0.85%
2026-09-18
Financials
Valuation Metrics
SCM Lifescience Co., Ltd.'s Market Cap is ₩229B. At end of 2025 it was ₩488B. Ranked #2258 of 2,421 in KR market (top 93%), #1493 of 1,640 on KOSDAQ (top 91%), #224 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 22.89B KRW | KR#2,258/2,421 Sec#224/231 |
| Revenue | 49.86B KRW | KR#1,793/2,421 Sec#123/231 |
| Net Income | -4.04B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 48.02B KRW | KR#2,227/2,421 Sec#205/231 |
| Net Assets | 32.29B KRW | KR#2,151/2,421 Sec#190/231 |
| Employees | 56 | KR#2,005/2,421 Sec#180/231 |
| Value | ||
| P/B | 0.71x | KR#1,138/2,421 Sec#65/231 |
| P/S | 0.46x | KR#866/2,421 Sec#38/231 |
| FCF Yield | -43.22% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -12.51% | KR#1,985/2,421 Sec#150/231 |
| ROA | -8.41% | KR#2,065/2,421 Sec#153/231 |
| Op. Margin | -9.19% | KR#1,975/2,421 Sec#134/231 |
| Revenue Growth | 3131.47% | KR#2/2,421 Sec#1/231 |
| Financial Health | ||
| Debt Ratio | 48.73% | KR#942/2,421 Sec#106/231 |
| Total Debt | 3.78B KRW | KR#1,835/2,421 Sec#176/231 |
| FCF | -9.89B KRW | KR#1,706/2,421 Sec#148/231 |
| Cash | 4.81B KRW | KR#2,018/2,421 Sec#187/231 |
| Current Ratio | 2.23x | KR#788/2,421 Sec#92/231 |
| Performance | ||
| 1Y Return | -61.48% | KR#2,220/2,421 Sec#209/231 |
| 1M Return | -7.23% | KR#1,943/2,421 Sec#158/231 |
| From 52W High | -65.58% | KR#2,054/2,421 Sec#170/231 |
| 1Y MDD | -63.35% | KR#1,660/2,421 Sec#137/231 |
| Trading | ||
| Volume | 14,515 shares | KR#1,756/2,421 Sec#173/231 |
| Trading Value | 34.0M KRW | KR#1,977/2,421 Sec#203/231 |
| Foreign Own. | 2.00% | KR#1,628/2,421 Sec#158/231 |
| Per Share | ||
| EPS | -419 KRW | KR—/2,421 Sec—/231 |
| BPS | 3,350 KRW | KR#1,782/2,421 Sec#135/231 |
Company Info
동사는 2014년 층분리배양법을 기반으로 설립된 줄기세포치료제 연구개발 바이오 기업임. 고순도·고효능 줄기세포치료제를 개발하며, 만성 이식편대숙주질환 2상, 중등증-중증 급성 췌장염 1/2a상, 중등증-중증 아토피 피부염 1/2상 임상시험을 운영 중임. 말레이시아 Duopharma Biotech Berhad와 동남아 4개국 독점 판매권 계약, 한독과 국내 아토피 피부염 기술이전 계약을 체결하며 글로벌 시장 진출을 확대하고 있음. 에스씨엠생명과학는 2014년에 설립되었으며 인천광역시 연수구에 본사를 두고 있습니다.